Potential of improving the treatment of tuberculosis through nanomedicine

Boitumelo Semete, Lonji Kalombo, Lebogang Katata, Paul Chelule, Laetitia Booysen, Yolandy Lemmer, Saloshnee Naidoo, Bathabile Ramalapa, Rose Hayeshi, Hulda S. Swai

Research output: Contribution to conferencePaper

7 Citations (Scopus)


Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200-300 nm were synthesized, with a drug encapsulation efficiency of 50-65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. © Taylor & Francis Group, LLC.
Original languageEnglish
Number of pages14
Publication statusPublished - 1 Jun 2012
Externally publishedYes
EventMolecular Crystals and Liquid Crystals -
Duration: 1 Jun 2012 → …


ConferenceMolecular Crystals and Liquid Crystals
Period01/Jun/12 → …


Dive into the research topics of 'Potential of improving the treatment of tuberculosis through nanomedicine'. Together they form a unique fingerprint.

Cite this